Biomarkers for placenta accreta spectrum (PAS) disorders
Methods and compositions for detecting or determining a subject's risk of developing placenta accreta spectrum (PAS) are provided. Biomarkers are described that can be useful in detecting PAS in the second or third trimester of pregnancy.
1 . A method for characterizing placenta accreta spectrum biomarkers in a biological sample, the method comprising contacting a biological sample of the subject with a panel comprising four distinct capture molecules bound to a substrate, each of which specifically binds one of the following polypeptide or polynucleotide biomarkers: antithrombin III, plasminogen activator inhibitor 1, soluble Tie2, and soluble VEGF receptor 2, wherein the biological sample is a maternal plasma sample.
2 . A method for characterizing placenta accreta spectrum in a pregnant subject, the method comprising characterizing placenta accreta spectrum biomarkers in a biological sample of a pregnant subject using a panel comprising three distinct capture molecules bound to a substrate, each of which specifically binds one of the following biomarkers: antithrombin III, soluble Tie2, and soluble VEGF receptor 2;
wherein the biological sample is a maternal plasma sample; and
wherein the method comprises contacting the biological sample with the panel.
3 . The method of claim 2 , wherein the subject is in the third trimester of pregnancy.
4 . The method of claim 2 , further comprising
determining the body mass index (BMI), obtaining imaging of the uterus of the subject, and or acquiring a clinical history of the subject.